Transcatheter valve therapy is moving rapidly from the aortic to the mitral valve. Transcatheter mitral valve therapy has been available and is approved for repair of degenerative mitral valve disease in patients who are deemed high risk for cardiac surgery. 1 The purpose of this review will be to address how transcatheter mitral valve therapy is rapidly going to change the treatment of mitral valve disease-both with regard to repair and replacement of the mitral valve.
FDA-Approved Therapy for Mitral Regurgitation
The Food and Drug Administration (FDA) approved the MitraClip for treatment of degenerative mitral valve regurgitation in 2013. There was one randomized controlled trial and a registry-based study that provided evidence for benefit with MitraClip. 1, 2 The randomized trial that directly compared MitraClip to mitral valve surgery demonstrated that the reduction of mitral regurgitation (MR) was superior with surgery compared with the MitraClip at 1 year of follow-up. However, the safety of the MitraClip was superior to surgical treatment-with the principal component of the major adverse events being the high rate of transfusion of >2 units of packed red blood cells in the surgery group (45%) versus the MitraClip group (13%). Despite the greater reduction in MR severity at 1 year in the surgical group, the reduction in left ventricular dimensions, the improvement of NYHA (New York Heart Association) class, and quality of life was similar in both groups. Of note, in a non-prespecified analysis, patients older than age 70 and patients with functional MR were important subgroups in which surgery failed to demonstrate a superior efficacy to MitraClip. The durability of the MitraClip results was subsequently reported at 5 years. 3 The EVEREST II High-Risk Registry evaluated patients who underwent MitraClip placement for whom surgery was deemed high risk by a Society of Thoracic Surgeons (STS) predicted risk of mortality of ≥12%.
2 This cohort of patients was very different from the previously discussed randomized controlled trial patients. The mean age of this high-risk group was 76 years of age, 60% had undergone prior cardiac surgery, and the average left ventricular ejection fraction was 47%. In this high-risk cohort, there were more major adverse events with death and stroke reflecting 4.8% and 2.2% of this cohort, respectively. MitraClip was quite effective at reducing MR as it was graded as ≤2+ in 84% of the patients. Physical and mental quality of life improved from baseline. Last, the annual rate of hospitalization for heart failure fell dramatically from 0.79% preprocedure to 0.41% postprocedure. In this high-risk registry, the concept of the heart team emerged as critically important to selecting patients. The surgeon co-investigator at the study site was instrumental in the definition of many high-risk patients who did not meet an absolute STS risk calculator mortality of 12%. 4 COAPT randomized patients with heart failure and functional MR to guideline-directed medical therapy versus MitraClip. This study has recently reached full enrollment of its target patients, and patients are still enrolled under a continuous access protocol while the data are undergoing analysis. It is anticipated that COAPT will add important insights to the treatment of functional MR.
Transcatheter Mitral Valve Replacement
The initial experience in using transcatheter valves for mitral valve therapy comes from the treatment of failing surgical bioprostheses or mitral rings. In this particular case, typically the off-label use of a transcatheter aortic valve-most commonly the Sapien 3 valve-has been employed. To date, the experience is limited, but a large international Transcatheter Mitral Valve Replacement (TMVR) Registry exists. Yoon and colleagues published a series of 248 patients from this registry undergoing TMVR. 5 Of note, all of these patients were deemed surgically high risk and were offered TMVR. This group had a mean STS predicted risk of mortality of 9%. Of the 248 patients, 176 had failing bioprostheses (valve-in-valve [ViV] group) and 72 had mitral repairs with ring annuloplasty (valve-in-ring [ViR] group). It is noteworthy that the failed bioprosthetic valve group (ViV) had mixed regurgitation and stenosis as a common mode of failure, whereas the mitral repair with ring group (ViR) had regurgitation as the predominant mode of failure. Transeptal access occurred in 33% of the patients, and transapical access was undertaken in 67%. While the overall mortality was quite low at 1.2%, important differences were observed. The overall technical success was higher in the ViV group compared with the ViR group. The ViR group required a greater number of second valve deployments and had more significant MR following the transcatheter implantation. Last, the 1-year all-cause mortality was higher in the ViR group than the ViV group. In summary, the off-label use of a transcatheter aortic valve has reasonable results when placed inside a failing mitral bioprosthesis. The outcomes of a transcatheter aortic valve for a failed mitral valve repair with ring annuloplasty remain quite inferior to the outcomes seen with valve-in-valve.
Another high surgical risk group of patients for surgical mitral valve replacement (MVR) include those with significant mitral annular calcification. Guerrero and colleagues examined outcomes of off-label transcatheter aortic valves in patients with mitral annular calcification who were deemed high surgical risk for a surgical MVR. 6 The mean STS risk score in this cohort was 14%. For perspective, this markedly elevated risk is comparable to the initial PARTNER Trial 7 with regard to surgical risk. In this report, the technical success rate was fairly low-at 72%-owing to the need to place a second valve in 17% of the patients. The 30-day mortality was 29% with noncardiac cause of mortality representing 17% of the overall mortality. These results remain sobering as despite the use of catheter-based techniques, the high short-term mortality reflected the late stage of presentation for treatment in combination with multiple co-morbid conditions.
There are several clinical trials that are set to launch in the United States that utilize dedicated transcatheter mitral valve prostheses to treat native mitral valve regurgitation in patients who were at high risk to undergo surgical MVR. These trials are all feasibility trials and are not randomized. At present, one transcatheter mitral valve has its initial feasibility results from a global trial reported. 8 The Tendyne transcatheter valve was implanted in 30 patients deemed to be at high risk for a surgical MVR. Twentyeight of 30 patients underwent successful placement of this device, which is placed transapically. One death occurred at postprocedure day 13, and one patient had evidence of leaflet thrombosis, which resolved with intensification of anticoagulation. At 30-day follow-up, 75% of patients reported mild or no symptoms.
The transcatheter mitral valve treatment of native mitral valve disease is more complex than transcatheter treatment of aortic valve disease. Issues such as left ventricular tract obstruction, valve migration, and dealing with a much more complex structure with an oval annulus, chordae tendineae, and the heterogeneity of mitral valve regurgitation patients will create different challenges for this technology. While the cardiovascular community is just embarking on catheter-based valve replacements, it is important to keep the extensive MitraClip experience in perspective as a guide to therapeutic evolution to deal with the challenges of TMVR. It is with great anticipation that these feasibility trials commence to offer treatment to high-risk surgical MVR patients.
Extending the Repair Into the Arch for Acute Type A Dissections
The paradigm for treatment of type A aortic dissection has been to get the patient off the table to fight another day. This was a shift to improved outcomes from early attempts to resect the entire dissection with very poor outcomes. 9 As we have discussed in the past Noteworthy articles, the long-standing treatment paradigm for type B dissections medically until complications paradigm is in evolution as is the restriction of type A repair to ascending aortic replacement. 10 Parallel to thoracic endovascular aortic repair (TEVAR) pushing the paradigm for type B dissections, the rapidly evolving technology of hybrid grafts, or the desire for them, has pushed the extent of type A repair as well.
The hesitation to do more extensive aortic replacement has been concerns of increased morbidity and mortality with inclusion of the brachiocephalic vessels. For many years, the arch replacement was looked down upon and the published outcomes were worse because they were reserved for the worst anatomic and physiologic situations. However, the argument for arch replacement remains that the arch cannot further degenerate, and with the frozen elephant trunk, the proximal descending aorta is also potentially remodeled as centers began expanding the resection many of these types of concerns have fallen out. In the first article reviewed here, Colli et al report a retrospective evaluation of patients undergoing aortic arch replacement in the absence of arch intimal tear. 11 They identified 135 cases from 1998 to 2015 with an arch mortality significantly higher than the less aggressive procedure (38% vs 21%, P = .004). However, the small numbers suggested that long-term mortality and late aortic reintervention rates were better, but did not show significance (7% vs 30%, P = .36, and 27% vs 14%, P = NS, respectively). This trend is the interesting part for centers that follow and care for these patients long term. Of note, one third of this cohort received antegrade cerebral perfusion for neuroprotection and the mean follow-up was only 5 years. So even though this study does not demonstrate any statistical benefit of extended arch replacement, it is pushing in the direction of long-term support of extensive aortic replacement.
Jumping with both feet into an arch replacement on a case that can already have substantial risk of bleeding can be intimidating. The next article attempts to diminish the aortic bleeding potential by comparing open and debranching elephant trunks. To be clear, most debranching approaches are essentially elephant trunks with alternative management of the brachiocephalic vessels. Ma and colleagues published an impressive series by number over a 3-year period. 12 They impressively compared 168 arch replacements of this time period with 132 being frozen elephant trunks and 32 hybrid debranching cases. By their definitions the frozen elephant was a full arch with an antegrade stent, while the debranching was an ascending replacement with debranching of the brachiocephalic vessels. The debranching group had significantly shorter bypass runs, and the debranching group had no circulatory arrest. The mortalities were significantly less with debranching (14.4% vs 5.6%, P = NS), but the Achilles Heel of debranching has been stroke. In this series, the stroke rates were identical at just over 5%. Obviously, this was a foreign study as body mass index >25 was associated with multisystem organ failure, which in and of itself would be an outlier in most US practices. They did demonstrate excellent midterm results with the 3-year survival rate of 76.1% in the elephant trunk group and 82.5% in the debranching group (P = NS). Despite the lack of comparison to an ascending aorta/hemiarch group, the overall outcomes of both these groups were impressive. It shows that extensive resection can be done safely and that even the debranching approach is feasible, at least in small patients.
Short of doing a randomized control study, the IRAD cohort may be the best representation of high-performing aortic center results currently available. Larsen and the IRAD investigators published the outcomes of extended versus limited arch replacement within the database. 13 The limited replacement included both ascending and hemiarch replacements. The in-hospital mortality was similar between the groups (limited 13.1% vs extended 17.1%, P = NS). Notably, both the overall 5-year survival (limited 69.4% vs extended 73.1%, P = NS) and the 5-year freedom from death, aortic rupture, and reintervention were similar (limited 71.1% vs extended 76.4%, P = NS). So even within this aggressive group of aortic centers, no difference between the 2 approaches can be demonstrated. Of course, this collective includes centers with an arch first approach and those that reserve arch replacements for more complex pathology. So the overall ability to discern between the approaches remains elusive.
Of note, the advancement of technology is pushing some of the extension of aortic arch intervention. Shrestha et al recently published their German experience with the hybrid grafts currently in evaluation in the United States. 14 Of their 251 hybrid graft elephant trunks, 52 patients had acute type A dissection repairs. Their dissection mortality was impressive at 12%. In their overall cohort, they had a 2% risk of spinal cord injury. Of the 49 patients requiring further intervention, half of them were endovascular. They have the most extensive experience published with the technology that is currently facilitating the aggressive approach to aortic dissection care. As more centers become comfortable with the use of this technology, the extended aortic repair could become more common in acute aortic dissection with the potential for improved aortic remodeling resulting from the stent in the proximal descending.
In summary, many centers are becoming more aggressive with aortic arch replacement for type A aortic dissections extending into the arch, which at least outside the United States may be secondary to the availability of hybrid aortic grafts. Currently, the literature suggests that total arch replacement may not be any riskier than more limited resection. It also suggests that long-term survival and reintervention trends toward benefit of more extensive aortic remodeling. However, this data are far from conclusive such that the paradigm should be altered across all centers caring for patients with aortic dissection.
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